论文部分内容阅读
本文对30例晚期腹部肿瘤患者rIL－2／LAK治疗前后的免疫功能进行动态观察。检测指标包括T细胞亚群（CD3、CD4、CD8及CD4／CD8）。淋巴细胞转化试验（LymphocytesBlastogenesisTestLBT）和NK细胞活性。结果表明：肿瘤患者经rIL－2／LAK治疗后，CD3、CD4明显升高．CD8也略有升高．CD4／CD8明显升高；淋巴细胞转化率明显升高；经rIL－2／LAK治疗后，NK细胞活性增强。这反映肿瘤患者经rIL－2／LAK治疗后机体细胞免疫功能得到增强。
This article dynamically observed the immune function of patients with advanced abdominal tumor before and after rIL-2/LAK treatment. Test indicators include T cell subsets (CD3, CD4, CD8, and CD4/CD8). Lymphocytes Blastogenesis Test LBT and NK cell activity. The results showed that after treatment with rIL-2/LAK, CD3 and CD4 were significantly elevated in tumor patients. CD8 also slightly increased. CD4/CD8 was significantly elevated; lymphocyte transformation rate was significantly increased; NK cell activity was enhanced after rIL-2/LAK treatment. This reflects the enhanced cellular immune function of tumor patients treated with rIL-2/LAK.